Search
for
Sort by
Research 331–360 of 577
- Evaluation of the Efficacy and Safety of Oral Tofacitinib for the Treatment of Alopecia Areata in Children
- 83 Transcriptomic meta-analysis and deconvolution approaches unveil cellular dynamics in scarring and non-scarring primary lymphocytic alopecias
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- Treatments for alopecia areata: a network meta-analysis
- 43853 Case of Reactive Keratoacanthomas arising Eight Years After Multicolored Tattoo Placement
- Janus kinase inhibitor as a therapeutic option in alopecia areata. Case report
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Reply to early onset effluvium secondary to COVID-19 and body-hair effluvium
- Phytotherapeutic Interventions using Rodent Models of Hair Loss: Current Research and Future Strategy
- Mesenchymal-epidermal interactions in hair follicle cycling and regeneration
- Faculty Opinions recommendation of Hair regrowth following a Wnt- and follistatin containing treatment: safety and efficacy in a first-in-man phase 1 clinical trial.
- The JAK/STAT signaling pathway: from bench to clinic
- Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
- Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- Skin Pigmentation Types, Causes and Treatment—A Review
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- A Subset of TREM2+ Dermal Macrophages Secretes Oncostatin M to Maintain Hair Follicle Stem Cell Quiescence and Inhibit Hair Growth
- Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib
- Alopecia Areata: An Updated Review for 2023
- The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials
- Understanding autoimmunity of vitiligo and alopecia areata
- Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention
- Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases
- Alopecia Areata: Current Treatments and New Directions
- Alopecia areata: What’s new in epidemiology, pathogenesis, diagnosis, and therapeutic options?
- Frontiers in alopecia areata pathobiology research